Julio Arrizabalaga

971 total citations
20 papers, 479 citations indexed

About

Julio Arrizabalaga is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Julio Arrizabalaga has authored 20 papers receiving a total of 479 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 11 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Julio Arrizabalaga's work include HIV Research and Treatment (11 papers), HIV/AIDS Research and Interventions (10 papers) and HIV/AIDS drug development and treatment (7 papers). Julio Arrizabalaga is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS Research and Interventions (10 papers) and HIV/AIDS drug development and treatment (7 papers). Julio Arrizabalaga collaborates with scholars based in Spain, Pakistan and United States. Julio Arrizabalaga's co-authors include Fernando Ballester Laguna, José Antonio Iribarren, Rafael Rubio, Juan Berenguer, Hernando Knobel, Anna Cruceta, Juan Luís Gómez-Sirvent, Peré Domingo, Francisco Rodríguez-Arrondo and Joan Romeu and has published in prestigious journals such as Clinical Infectious Diseases, CHEST Journal and AIDS.

In The Last Decade

Julio Arrizabalaga

20 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julio Arrizabalaga Spain	12	314	213	140	85	43	20	479
Laurence Bocket France	13	339 1.1×	304 1.4×	144 1.0×	55 0.6×	14 0.3×	58	558
Ka-Hing Wong China	13	340 1.1×	224 1.1×	267 1.9×	18 0.2×	21 0.5×	38	510
Maria Grazia Milia Italy	15	299 1.0×	56 0.3×	182 1.3×	37 0.4×	14 0.3×	26	491
Jane Yeats South Africa	8	208 0.7×	68 0.3×	81 0.6×	16 0.2×	7 0.2×	9	293
S Villar del Saz Spain	12	154 0.5×	99 0.5×	173 1.2×	57 0.7×	25 0.6×	14	382
Sandra Rae Canada	8	383 1.2×	337 1.6×	129 0.9×	12 0.1×	18 0.4×	12	553
Cécile Peltier France	9	272 0.9×	89 0.4×	137 1.0×	27 0.3×	2 0.0×	15	387
Vítor Duque Portugal	10	156 0.5×	109 0.5×	62 0.4×	70 0.8×	16 0.4×	28	293
Véronique Brodard France	12	170 0.5×	48 0.2×	253 1.8×	125 1.5×	16 0.4×	25	485
A Beaumel Ivory Coast	8	502 1.6×	111 0.5×	481 3.4×	51 0.6×	4 0.1×	9	726

Countries citing papers authored by Julio Arrizabalaga

Since Specialization

Citations

This map shows the geographic impact of Julio Arrizabalaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julio Arrizabalaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julio Arrizabalaga more than expected).

Fields of papers citing papers by Julio Arrizabalaga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julio Arrizabalaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julio Arrizabalaga. The network helps show where Julio Arrizabalaga may publish in the future.

Co-authorship network of co-authors of Julio Arrizabalaga

This figure shows the co-authorship network connecting the top 25 collaborators of Julio Arrizabalaga. A scholar is included among the top collaborators of Julio Arrizabalaga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julio Arrizabalaga. Julio Arrizabalaga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ascaso, Ana, Javier García‐Pérez, Mayte Pérez‐Olmeda, et al.. (2022). Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. EClinicalMedicine. 51. 101542–101542. 4 indexed citations

Miró, José M., Christian Manzardo, Peré Domingo, et al.. (2010). Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results (The Advanz Trial): A Randomized, Controlled Trial. AIDS Research and Human Retroviruses. 26(7). 747–757. 16 indexed citations

Rodríguez‐Baño, Jesús, Julio Arrizabalaga, Juan Berenguer, Javier Garau, & José María Gatell. (2008). La infectología en Europa y América. Enfermedades Infecciosas y Microbiología Clínica. 26. 15–22. 1 indexed citations

Arrizabalaga, Julio, et al.. (2008). Tuberculosis en la comarca del Bajo Deba (Guipúzcoa) en el período 1995-2006. Enfermedades Infecciosas y Microbiología Clínica. 26(4). 187–193. 4 indexed citations

Arrizabalaga, Julio, Piedad Arazo, Koldo Aguirrebengoa, et al.. (2007). Effectiveness and Safety of Simplification Therapy with Once-Daily Tenofovir, Lamivudine, and Efavirenz in HIV-1–Infected Patients with Undetectable Plasma Viral Load on HAART. HIV Clinical Trials. 8(5). 328–336. 10 indexed citations

Arrizabalaga, Julio, Josune Goikoetxea, José Antonio Iribarren, et al.. (2004). Características epidemiológicas de las nuevas infecciones causadas por el VIH comparadas con los casos de sida. La epidemia de VIH/sida en el País Vasco. Gaceta Sanitaria. 18(2). 145–149. 7 indexed citations

Rodríguez‐Valadez, Francisco J., Julio Arrizabalaga, J. Corral, et al.. (2004). Características epidemiológicas de las nuevas infecciones causadas por el VIH comparadas con los casos de sida. La epidemia de VIH/sida en el País Vasco. Gaceta Sanitaria. 18(2). 145–149. 10 indexed citations

Torres-Tortosa, M., et al.. (2003). Prognosis and Clinical Evaluation of Infection Caused by Rhodococcus equi in HIV-Infected Patientsa. CHEST Journal. 123(6). 1970–1976. 64 indexed citations

Berenguer, Juan, Pilar Miralles, Julio Arrizabalaga, et al.. (2003). Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral Therapy. Clinical Infectious Diseases. 36(8). 1047–1052. 95 indexed citations

10.

Rubio, Rafael, Juan Berenguer, José M. Miró, et al.. (2002). Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002. Enfermedades Infecciosas y Microbiología Clínica. 20(6). 244–303. 38 indexed citations

11.

Cilla, Gustavo, Berta Rodés, Emilio Pérez‐Trallero, Julio Arrizabalaga, & Vincent Soriano. (2001). Molecular Evidence of Homosexual Transmission of HIV Type 2 in Spain. AIDS Research and Human Retroviruses. 17(5). 417–422. 16 indexed citations

12.

Romeu, Joan, Hernando Knobel, Julio Arrizabalaga, et al.. (2000). Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1???Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 25(1). 26–35. 14 indexed citations

13.

García, Felipe, Hernando Knobel, M. A. Sambeat, et al.. (2000). Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the Scan Study. AIDS. 14(16). 2485–2494. 33 indexed citations

14.

García, Felipe, Joan Romeu, Hernando Knobel, et al.. (2000). Comparison of Immunologic Restoration and Virologic Response in Plasma, Tonsillar Tissue, and Cerebrospinal Fluid in HIV-1–Infected Patients Treated With Double Versus Triple Antiretroviral Therapy in Very Early Stages: The Spanish Earth-2 Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 25(1). 26–35. 21 indexed citations

15.

Knobel, Hernando, C Codina, Alexia Carmona, et al.. (2000). [The recommendations of GESIDA/SEFH/PNS for improving adherence to antiretroviral treatment. AIDS Study Group of the Spanish Society of Hospital Pharmacy and the National Plan on AIDS of the Minister of Health and Consumers].. PubMed. 18(1). 27–39. 27 indexed citations

16.

García, Felipe, Joan Romeu, Inmaculada Grau, et al.. (1999). A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS. 13(17). 2377–2388. 43 indexed citations

17.

Casado, José L., Julio Arrizabalaga, Marisa Montes, et al.. (1999). Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. AIDS. 13(12). 1497–1502. 41 indexed citations

18.

Wichmann, M. A. von, et al.. (1998). [Pulmonary cavitation lesions in patients infected with the human immunodeficiency virus: an analysis of a series of 78 cases].. PubMed. 111(19). 725–30. 9 indexed citations

19.

Iribarren, José Antonio, et al.. (1997). AIDS-Associated Cryptosporidiosis With Antral Narrowing. Journal of Clinical Gastroenterology. 25(4). 693–694. 4 indexed citations

20.

Arrizabalaga, Julio, et al.. (1993). CD8+CD38+ and CD8+DR+ Peripheral Blood Lymphoid Subsets of HIV-Infected Intravenous Drug Abusers Correlate with CD4+ Cell Counts and Proliferation to Mitogens. Cellular Immunology. 150(1). 72–80. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact